

The UroLift System is a minimally invasive procedure used to treat BPH. It is the only leading enlarged prostate treatment that does not require heating, cutting or removal of prostate tissue.¹⁻⁶

Indications for use:

The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to BPH in men 50 years or older.

Contraindications:

The UroLift System should not be used if the patient has:

- Prostate volume is > 100cc
- A urinary tract infection



UROLIFT

Pre-procedure

UroLift

Delivery Device

Post-procedure



The benefits of the UroLift System for patients are:

- Patients are generally discharged post-op without a catheter^{1,7}
- Rapid improvement in symptoms and quick recovery^{1,7}
- The only leading BPH procedure shown to not cause new and lasting sexual dysfunction^{#2,4,9}
- May be suitable for patients who do not want to undergo major surgery due to risks of complications and side effects^{11,14}
- Better symptom relief than medications^{1,2}
- Lower risk profile than TURP¹⁴
- Rapid relief and recovery^{1,7}

The benefits of the UroLift System for the health care system are:

- Can be performed as a daycase or an outpatient procedure⁷
- Can be performed under local anaesthesia⁷
- Helps to reduce waiting lists and release theatre capacity¹⁵
- Patients are generally discharged from the hospital or the outpatient clinic within a couple of hours post procedure¹⁵

References

*No instances of new, sustained erectile or ejaculatory dysfunction in the LIFT pivotal study

1. Roehrborn, J Urol 2013; 2. AUA Guidelines 2003, 2020; 3. Mirakhur, Can Assoc Radiol J 2017; 4. McVary, J Urol 2016; 5. Gilling, Can J Urol 2020; 6. Kadner, World J Urol 2020; 7. Shore, Can J Urol 2014; 8. Bachmann, European Eurol 2013; 9. Roehrborn, Can J Urol 2017 L.I.F.T. Study; 10. Naspro, Eur Urol 2009; 11. Montorsi, J Urol 2008; 12. McVary, J Sex Med 2016; 13. Roehrborn, Can J Urol 2017; 14. Sonksen, Eur Urol 2015; 15. NICE shared learning RD & E (Tiverton) Nov 2019; 16. NICE shared learning: Treating Benign Prostatic Obstruction with UroLift in an outpatient setting, 2020; 17. EAU Guidelines Management of Non-neurogenic Male LUTS

Teleflex is a registered trademark of Teleflex Incorporated or its affiliates. © 2021 Teleflex Incorporated. All rights reserved. MCI-2021-0448-EN · Rev 1 · 08 21 PDF

